Prevalence and associated factors of dysphonia in non-hospitalized Thai COVID-19 patients: a descriptive study with Thai-VHI10 Assessment.

IF 0.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Asian Biomedicine Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI:10.2478/abm-2024-0037

Thitaree Suwannutsiri, Peerada Arreenich, Premsuda Sombuntham

{"title":"Prevalence and associated factors of dysphonia in non-hospitalized Thai COVID-19 patients: a descriptive study with Thai-VHI10 Assessment.","authors":"Thitaree Suwannutsiri, Peerada Arreenich, Premsuda Sombuntham","doi":"10.2478/abm-2024-0037","DOIUrl":null,"url":null,"abstract":"Background: The COVID-19 pandemic first emerged in December 2019 and rapidly spread globally, including Thailand. While respiratory symptoms remain the primary manifestation of the disease, upper respiratory tract symptoms, including dysphonia, have been reported in various studies.Objectives: To determine the prevalence of dysphonia in non-hospitalized Thai COVID-19 patients and identify associated factors using the Thai-Voice Handicap Index-10.Methods: This study investigates the prevalence of dysphonia and associated factors in non-hospitalized Thai COVID-19 patients. Conducted from September 2022 to February 2023, it enrolled healthcare workers who tested positive for COVID-19 but were not hospitalized.Results: Among 82 patients, 53 (64.6%) reported dysphonia, which was significantly associated with cough (P = 0.013) and nasal discharge (P = 0.047). Substantial improvement was observed at the 3-month follow-up (73.6%). Vaccination may serve as a protective factor (crude odds ratio < 1).Conclusion: The prevalence of dysphonia among non-hospitalized COVID-19 patients in Thailand is 63.6%, linked to cough and nasal congestion, with symptoms likely to subside within 3 months.","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"297-302"},"PeriodicalIF":0.4000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650421/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/abm-2024-0037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The COVID-19 pandemic first emerged in December 2019 and rapidly spread globally, including Thailand. While respiratory symptoms remain the primary manifestation of the disease, upper respiratory tract symptoms, including dysphonia, have been reported in various studies.

Objectives: To determine the prevalence of dysphonia in non-hospitalized Thai COVID-19 patients and identify associated factors using the Thai-Voice Handicap Index-10.

Methods: This study investigates the prevalence of dysphonia and associated factors in non-hospitalized Thai COVID-19 patients. Conducted from September 2022 to February 2023, it enrolled healthcare workers who tested positive for COVID-19 but were not hospitalized.

Results: Among 82 patients, 53 (64.6%) reported dysphonia, which was significantly associated with cough (P = 0.013) and nasal discharge (P = 0.047). Substantial improvement was observed at the 3-month follow-up (73.6%). Vaccination may serve as a protective factor (crude odds ratio < 1).

Conclusion: The prevalence of dysphonia among non-hospitalized COVID-19 patients in Thailand is 63.6%, linked to cough and nasal congestion, with symptoms likely to subside within 3 months.

查看原文本刊更多论文

泰国非住院COVID-19患者的发声障碍患病率及相关因素：一项泰国vhi10评估的描述性研究

背景：2019年12月首次出现COVID-19大流行，并迅速在全球蔓延，包括泰国。虽然呼吸道症状仍然是该病的主要表现，但在各种研究中也报道了上呼吸道症状，包括发音困难。目的：利用泰语语音障碍指数-10确定未住院的泰国COVID-19患者中语音障碍的患病率，并确定相关因素。方法：本研究调查泰国非住院COVID-19患者的发声障碍患病率及相关因素。该研究于2022年9月至2023年2月进行，招募了COVID-19检测呈阳性但未住院的医护人员。结果：82例患者中，有53例（64.6%）出现发声障碍，且与咳嗽（P = 0.013）和流鼻液（P = 0.047）显著相关。在3个月的随访中观察到实质性改善（73.6%）。疫苗接种可能是保护因素（粗优势比< 1）。结论：泰国非住院COVID-19患者的发声障碍患病率为63.6%，与咳嗽和鼻塞有关，症状可能在3个月内消退。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Biomedicine 医学-医学：研究与实验

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Asian Biomedicine: Research, Reviews and News (ISSN 1905-7415 print; 1875-855X online) is published in one volume (of 6 bimonthly issues) a year since 2007. [...]Asian Biomedicine is an international, general medical and biomedical journal that aims to publish original peer-reviewed contributions dealing with various topics in the biomedical and health sciences from basic experimental to clinical aspects. The work and authorship must be strongly affiliated with a country in Asia, or with specific importance and relevance to the Asian region. The Journal will publish reviews, original experimental studies, observational studies, technical and clinical (case) reports, practice guidelines, historical perspectives of Asian biomedicine, clinicopathological conferences, and commentaries Asian biomedicine is intended for a broad and international audience, primarily those in the health professions including researchers, physician practitioners, basic medical scientists, dentists, educators, administrators, those in the assistive professions, such as nurses, and the many types of allied health professionals in research and health care delivery systems including those in training.